Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Propanc is a development-stage biopharmaceutical company focused on creating non-toxic cancer treatments, specifically its lead product candidate PRP (a pro-enzyme formulation). The company has no commercial revenue and relies on equity and debt financing to fund research and development (R&D) and operations. The company is incorporated in Delaware with principal executive offices in Australia.
Key Financial Metrics
| Metric | Q1 2025 (Three Months Ended Sept 30) | Q1 2024 (Three Months Ended Sept 30) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,837,738) | $(354,310) |
| Net Loss Per Share (Basic & Diluted) | $(0.39) | $(35.97) |
| Cash and Cash Equivalents (End of Period) | $602,737 | $9,268 |
| Total Assets | $17,975,681 | $19,631,808 |
| Total Liabilities | $3,614,514 | $5,725,616 |
| Stockholders' Equity | $14,361,167 | $13,906,192 |
| Accumulated Deficit | $(130,459,258) | $(125,621,520) |
Operating Expenses: Total operating expenses were $4,673,564, driven primarily by Administration expenses of $4,598,574 (up from $220,759 in the prior year). R&D expenses were $60,201.
Debt and Liquidity: The company holds significant prepaid expenses ($17.2M total) related to equity instruments issued for services. Current liabilities include approximately $107k in convertible notes and $460k in related party loans. The company reported a net cash increase of $590,649 for the quarter, primarily due to financing activities.
Material Changes vs. Prior Period
- Significant Increase in Net Loss: Net loss increased by approximately $4.48 million compared to the prior year quarter. This is largely attributable to a $3.74 million increase in stock-based consulting expenses and higher interest expenses related to debt amortization and penalties.
- Capital Raise: In August 2025, the company completed an underwritten public offering of 1,000,000 shares at $4.00 per share, generating gross proceeds of $4.0 million and net proceeds of approximately $3.3 million. This significantly improved cash balances from $12,088 at the start of the quarter to $602,737.
- Debt Restructuring: The company repaid or converted a significant portion of its outstanding promissory notes and convertible debt during the quarter. Notes payable decreased from $543,312 (net) to $0, and convertible notes decreased from $537,921 (net) to $106,968 (net).
- Derivative Liabilities: Embedded conversion option liabilities decreased from $403,892 to $167,878 due to conversions and repayments, resulting in a net gain on extinguishment of debt of $195,861.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Despite the recent capital raise, the company has an accumulated deficit of over $130 million and relies on future financing to fund operations and R&D.
- Recent Developments: The company received a US patent grant for its "proenzyme composition" in September 2025. Shares commenced trading on the Nasdaq Capital Market under the ticker "PPCB" in August 2025.
- Unusual Items:
- Stock-Based Compensation: A major driver of expenses was the issuance of common stock for services, including a consulting agreement involving 500,000 shares valued at $1.365 million.
- Debt Defaults: As of September 30, 2025, the company was in default on certain loans (e.g., Crown Bridge Note and related party loans) totaling over $200k in principal and accrued interest.
- Subsequent Events: In October and November 2025, the company issued additional shares for debt conversions and services. On November 4, 2025, the company closed a private placement of Series C Preferred Stock with Hexstone Capital LLC for approximately $1.0 million.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including a lack of written documentation and insufficient segregation of duties.
Investor Verification Checklist
- Cash Runway: Verify if the $602k cash balance plus the $1.0M from the November Series C placement is sufficient to cover the high burn rate (approx. $4.8M loss per quarter) without immediate additional financing.
- Debt Obligations: Confirm the status of the defaulted loans (Crown Bridge and related party) and whether extensions or settlements have been finalized to avoid acceleration of debt.
- Stock Dilution: Review the impact of the recent equity issuances for services (consulting agreements) and debt conversions on existing shareholder ownership.
- Going Concern Status: Assess the feasibility of the company's plan to raise additional capital given the current market conditions and the "Going Concern" qualification in the audit report.
- Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting, which could impact the reliability of future filings.